These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 37012892)

  • 1. Generation and characterization of QLS22001, a humanized monoclonal antibody that neutralizes IL-17A and IL-17F with an extended half-life.
    Ma H; Zhang W; Liu K; Xu B; Li M; Meng Q; An Z; Chen B
    Int Immunopharmacol; 2023 Apr; 117():109947. PubMed ID: 37012892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.
    Oliveira DG; Faria R; Torres T
    Drug Des Devel Ther; 2021; 15():1045-1053. PubMed ID: 33727793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease.
    Cole S; Manghera A; Burns L; Barrett J; Yager N; Rhys H; Skelton A; Cole J; Goodyear CS; Griffiths M; Baeten D; Bertolini M; Shaw S; Al-Mossawi H; Maroof A
    J Allergy Clin Immunol; 2023 Sep; 152(3):783-798. PubMed ID: 37244461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.
    Navarro-Compán V; Puig L; Vidal S; Ramírez J; Llamas-Velasco M; Fernández-Carballido C; Almodóvar R; Pinto JA; Galíndez-Aguirregoikoa E; Zarco P; Joven B; Gratacós J; Juanola X; Blanco R; Arias-Santiago S; Sanz Sanz J; Queiro R; Cañete JD
    Front Immunol; 2023; 14():1191782. PubMed ID: 37600764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies.
    Sánchez-Rodríguez G; Puig L
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis.
    Yeremenko N
    Curr Opin Rheumatol; 2021 Jul; 33(4):333-340. PubMed ID: 34001692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
    Benschop RJ; Chow CK; Tian Y; Nelson J; Barmettler B; Atwell S; Clawson D; Chai Q; Jones B; Fitchett J; Torgerson S; Ji Y; Bina H; Hu N; Ghanem M; Manetta J; Wroblewski VJ; Lu J; Allan BW
    MAbs; 2019; 11(6):1175-1190. PubMed ID: 31181988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [IL-17A and IL-17F: from discovery to target of biologics - an illustrative example of translational research].
    Robert M; Miossec P
    Biol Aujourdhui; 2024; 218(1-2):33-39. PubMed ID: 39007775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23.
    Steere B; Beidler C; Martin A; Bright S; Kikly K; Benschop RJ
    J Pharmacol Exp Ther; 2023 Nov; 387(2):180-187. PubMed ID: 37714687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of interleukin-17A and 17F on cell interactions between immune cells and stromal cells from synovium or skin.
    Tout I; Noack M; Miossec P
    Sci Rep; 2023 Nov; 13(1):19223. PubMed ID: 37932356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-immune Diseases.
    Akhter S; Tasnim FM; Islam MN; Rauf A; Mitra S; Emran TB; Alhumaydhi FA; Khalil AA; Aljohani ASM; Al Abdulmonem W; Thiruvengadam M
    Curr Pharm Des; 2023; 29(26):2078-2090. PubMed ID: 37670700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
    Saviano A; Manosour AA; Raucci F; Merlino F; Marigliano N; Schettino A; Wahid M; Begum J; Filer A; Manning JE; Casillo GM; Piccolo M; Ferraro MG; Marzano S; Russomanno P; Bellavita R; Irace C; Amato J; Alfaifi M; Rimmer P; Iqbal T; Pieretti S; Vellecco V; Caso F; Costa L; Giacomelli R; Scarpa R; Cirino G; Bucci M; McGettrick HM; Grieco P; Iqbal AJ; Maione F
    Ann Rheum Dis; 2023 Nov; 82(11):1415-1428. PubMed ID: 37580108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy.
    Varkey R; Du Q; Karnell JL; Xiao X; Casey KA; Woods R; Rosenthal K; Wilson S; Dall'Acqua WF; Wu H; Herbst R; Ettinger R; Damschroder M
    PLoS One; 2019; 14(1):e0211236. PubMed ID: 30682117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking IL-17A prevents oxycodone-induced depression-like effects and elevation of IL-6 levels in the ventral tegmental area and reduces oxycodone-derived physical dependence in rats.
    Inan S; Meissler JJ; Bessho S; Wiah S; Tukel C; Eisenstein TK; Rawls SM
    Brain Behav Immun; 2024 Mar; 117():100-111. PubMed ID: 38199516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature.
    Bernardini N; Ambrosio L; Tolino E; Proietti I; Skroza N; Potenza C
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673523
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.
    Navarro-Compán V; Puig L; Vidal S; Ramírez J; Llamas-Velasco M; Fernández-Carballido C; Almodóvar R; Pinto JA; Galíndez-Aguirregoikoa E; Zarco P; Joven B; Gratacós J; Juanola X; Blanco R; Arias-Santiago S; Sanz JS; Queiro R; Cañete JD
    Front Immunol; 2023; 14():1332177. PubMed ID: 38077344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of 405B8H3(D-E), a newly engineered high affinity chimeric LAG-3 antibody with potent antitumor activity.
    Lan X; Yang TTC; Wang Y; Qu B; Rong S; Song N
    FEBS Open Bio; 2023 Jul; 13(7):1253-1265. PubMed ID: 37302810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Redirecting an anti-IL-1β antibody to bind a new, unrelated and computationally predicted epitope on hIL-17A".
    Fischman S; Levin I; Rondeau JM; Štrajbl M; Lehmann S; Huber T; Nimrod G; Cebe R; Omer D; Kovarik J; Bernstein S; Sasson Y; Demishtein A; Shlamkovich T; Bluvshtein O; Grossman N; Barak-Fuchs R; Zhenin M; Fastman Y; Twito S; Vana T; Zur N; Ofran Y
    Commun Biol; 2023 Sep; 6(1):997. PubMed ID: 37773269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition.
    Adams R; Bunick CG; Lawson ADG; Gomez B; Shaw S
    J Invest Dermatol; 2024 Apr; ():. PubMed ID: 38631666
    [No Abstract]   [Full Text] [Related]  

  • 20. IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration.
    Adamopoulos IE; Kuchroo V
    Nat Rev Rheumatol; 2023 Sep; 19(9):535-536. PubMed ID: 37488297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.